ArticleTherapeutic advances in medical oncology

Erratum to A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma.

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.